<DOC>
	<DOCNO>NCT01693653</DOCNO>
	<brief_summary>This double-blind placebo control study target individual active Behcet 's Syndrome oral ulcer resistant ( respond 4 week ) conventional treatment . Maximum allowable dose colchicine ( 0.6mg twice day ) stable dose 4 week enrollment . Prednisone equivalent ( &lt; 10mg/day ) permit dose stable 6 week prior enrollment . The study investigate safety tocilizumab vasculitic condition addition efficacy . The planned sample size 30 participant per arm total 60 participant . The study would 3 month , safety follow 2 month study termination . Study participant stay current treatment either tocilizumab placebo infusion give every 4 week addition . Patients randomize Actemra IV 8mg/kg Q 4 week X 3 dos placebo .</brief_summary>
	<brief_title>Tocilizumab Treatment Behcet 's Syndrome</brief_title>
	<detailed_description>Behcet 's syndrome vasculitis cause oral genital ulceration , skin lesion , eye disease arthritis , addition vascular complication thrombophlebitis , thrombosis rarely central nervous system involvement . IL-6 activity suggest pathogenesis study . Tocilizumab unique mode action among biologic agent may good candidate orphan disease .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>1 . Any patient BS least 1 active oral ulcer resistant ( respond 4 week colchicine local measure . 2. dose ( maximum allowable 0.6mg twice day ) stable 4 week prednisone equivalent ( maximum dose &lt; 10mg/day ) stable 6 week prior enrollment . 3 . Patients must Behcet 's syndrome base International Study Group criterion . Patients include trial base follow criterion : Normal organ function , except abnormal due disease investigation mucocutaneous involvement joint involvement . Men woman reproductive potential must agree use acceptable method birth control treatment twelve month completion treatment . Subject provide write informed consent . 1 . Patients eye , CNS , vascular involvement DVT , thrombosis , aneurysms . 2 . Patients currently treat expose last 3 month immunosuppressive medication ( azathioprine , TNF inhibitor , methotrexate , mycophenolate mofetil ) . Patients currently treat expose Cyclosporine cyclophosphamide past 6 month exclude ) . 3 . Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization . 4 . Treatment investigational agent within 4 week ( 5 halflives investigational drug , whichever long ) screening . 5 . Previous treatment celldepleting therapy , include investigational agent approve therapy , example CAMPATH , antiCD4 , antiCD5 , anti¬CD3 , antiCD19 antiCD20 ( please note exception ) . 6 . Treatment intravenous gamma globulin , plasmapheresis Prosorba column within 6 month baseline . 7 . Immunization live/attenuated vaccine within 4 week prior baseline . 8 . Previous treatment TCZ ( exception criterion may grant single dose exposure upon application sponsor casebycase basis ) . 9 . Any previous treatment alkylating agent chlorambucil , total lymphoid irradiation . 10 . History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody . 11 . Evidence serious uncontrolled concomitant cardiovascular , nervous system , pulmonary ( include obstructive pulmonary disease ) , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) gastrointestinal disease ( include complicate diverticulitis , ulcerative colitis , Crohn 's disease . ) 12 . Current liver disease determine principal investigator unless related primary disease investigation 13 . Known active current history recurrent bacterial , viral , fungal , mycobacterial infection ( include limit tuberculosis atypical mycobacterial disease , Hepatitis B C , herpes zoster , exclude fungal infection nail bed ) . 14 . Any major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week prior screen . 15 . Active TB require treatment within previous 3 year . Patients screen latent TB , positive , treat follow local practice guideline prior initiate TCZ . Patients treat tuberculosis recurrence 3 year permit . ( Appendix 8 ) 16 . Primary secondary immunodeficiency ( history currently active ) unless relate primary disease investigation . 17 . Evidence active malignant disease , malignancy diagnose within previous 10 year ( include hematological malignancy solid tumor , except basal squamous cell carcinoma skin carcinoma situ cervix uterus excise cure ) , breast cancer diagnose within previous 20 year unless related primary disease investigation . 18 . Pregnant woman nurse ( breast feeding ) mother . 19 . Patients reproductive potential willing use effective method contraception . 20 . History alcohol , drug chemical abuse within 1 year prior screen . 21 . Neuropathies condition might interfere pain evaluation unless related primary disease investigation . 22 . Patients lack peripheral venous access . Laboratory Exclusion criterion ( screen ) : 23 . Serum creatinine &gt; 1.6 mg/dL ( 141 µmol/L ) female patient &gt; 1.9 mg/dL ( 168 µmol/L ) male patient . Patients serum creatinine value exceed limit may eligible study estimate glomerular filtration rate ( GFR ) &gt; 30 . 24 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 time upper limit normal ( ULN ) 25 . Total Bilirubin &gt; ULN 26 . Platelet count &lt; 100 x 109/L ( 100,000/mm3 ) 27 . Hemoglobin &lt; 85 g/L ( 8.5 g/dL ; 5.3 mmol/L ) 28 . White Blood Cells &lt; 3.0 x 109/L ( 3000/mm3 ) 29 . Absolute Neutrophil Count &lt; 2.0 x 109/L ( 2000/mm3 ) 30 . Absolute Lymphocyte Count &lt; 0.5 x 109/L ( 500/mm3 ) 31 . Positive Hepatitis BsAg , Hepatitis C antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Behcet 's syndrome</keyword>
	<keyword>oral ulcer</keyword>
</DOC>